Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Industry Challenges FDA's User Fee Markup

This article was originally published in The Gray Sheet

Executive Summary

During the first round of user fee negotiations, industry questioned FDA's estimated cost of $750 million needed to continue the device user fee program between 2018 and 2022. Lobby groups for the device industry continue to emphasize user fees should supplement congressional appropriations to pay for FDA's review of devices.


Related Content

FDA, Industry Agree On Working Groups To Support User-Fee Negotiations
New Fundings And Goals To Match Raised In Latest MDUFA IV Session
Regulatory News: User-Fee Talks, 'Critical-To-Quality' Pilot, Genetic Screening Regs
More Resources Sought For Using Patient-Preference Data In Device Reviews
Congress Will Not Tinker With FDA LDT Guidance Before Final, Staffers Indicate
Apply User Fees To Postmarket Data Collection In MDUFA IV, Pew Argues
Calls For More FDA Training In Lead Up To User-Fee Negotiations
Device Industry Expects Quicker Path To Market In Exchange For Doubling Of User Fees





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts